# Neural Biomarkers of ECT Response in Schizophrenia

> **NIH NIH K23** · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · 2022 · $195,480

## Abstract

PROJECT SUMMARY
This is an application for an NIMH Mentored Patient-Oriented Research Career Development Award (K23)
entitled "Neural Biomarkers of ECT Response in Schizophrenia." In this application, Dr. Miklos Argyelan
proposes a comprehensive plan for transitioning into an independent translational researcher focused on
understanding the neural mechanisms of treatment response in schizophrenia by integrating functional
neuroimaging with neuromodulatory bioelectric treatment approaches.
Despite its effectiveness and intensive research, the mechanism of action for ECT remains unknown, and
currently no clinical or biological biomarkers exist to predict response. In patients with schizophrenia
undergoing a trial of ECT (with bitemporal electrode placement), the proposed study will use resting-state
functional MRI, as well as electrical field modeling as applied to structural MRI scans, to examine the neural
circuitry underlying clinical response. Patients will undergo MRI scanning at baseline, and after the 8th ECT
treatment. Results of this proposal may lead to biomarkers that will optimize treatment algorithms for
schizophrenia with higher efficacy. Identifying target mechanisms would not only improve the current
deployment of bioelectric approaches as part of a “precision medicine” approach, but could also lead to the
development of novel therapies.
This line of research will be conducted under the guidance of mentors who are recognized experts in the
biomarker research of schizophrenia (Anil K. Malhotra, M.D.), neuromodulation (Georgios Petrides, M.D.,
Marom Bikson Ph.D.), neuroimaging of ECT (Chris Abbott, M.D.) and analyzing high dimensional datasets
(Jing Sui, PhD.). Concurrently, Dr Argyelan will engage in a comprehensive training program which is fully
integrated with the research study in the proposal. The training plan contains three domains with corresponding
goals: (1) to gain further expertise in designing and conducting clinical trials in schizophrenia, (2) to expand my
knowledge in machine learning algorithms, and (3) to learn more about electrical field (EF) modeling
techniques. The combination of training in clinical trials, machine learning and neuromodulation will support the
planned research to provide the framework to explore and validate biomarkers of disease and treatment
response. The culmination of these training activities, combined with the planned research aims under this
award, will prepare Dr. Argyelan to develop into an independent translational researcher and to submit a
planned R01 in personalized neuromodulation.

## Key facts

- **NIH application ID:** 10364748
- **Project number:** 5K23MH120504-03
- **Recipient organization:** FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
- **Principal Investigator:** Miklos Argyelan
- **Activity code:** K23 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $195,480
- **Award type:** 5
- **Project period:** 2020-04-01 → 2024-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10364748

## Citation

> US National Institutes of Health, RePORTER application 10364748, Neural Biomarkers of ECT Response in Schizophrenia (5K23MH120504-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10364748. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*